Explore Evidence.
Shape Future Research.

A powerful evidence-based platform designed to transform complex cancer research landscapes into clear, interactive, and decision-ready insights.

This video introduces the World Health Organization (WHO) Classification of Tumours (WCT) Evidence Explorer and demonstrates how the platform transforms evidence into meaningful intelligence. You can explore curated evidence gap maps (EGMs) and use interactive dashboards to generate tailored outputs for decision-making and research planning. The platform is designed to make complex evidence landscapes accessible, transparent, and actionable.


In the EGMs tab, you will find several sample EGMs produced as part of the WCT EVI MAP project.
In the Dashboard tab, you will find a dashboard to explore the database built from the EGMs produced. Use the filters to focus on what matters to you, and the results will appear in interactive graphs to support easy analysis and interpretation.
In the EGM Builder tab, you can create a JSON file to build your own customized EGM. Based on your selection, the EGM will include articles from our database related to the chosen tumour sites and/or types. The JSON file can then be imported into the EPPI-Mapper software to generate the EGM.
In the Partners tab, you will find information about the project partners.
In the About Us tab, you will find information about the project team.
In the Methods Overview tab, you will find information about tumour characteristics, study design, and level of evidence.
In the Help tab, you will find video tutorials and step-by-step guides to help you navigate and use the website effectively.
About the evidence gap maps (EGMs): EGMs are visual tools that systematically summarize and display the published evidence on a topic across outcome domains, in this case tumour type (columns) and diagnostic tumour characteristics (rows). They can be used to identify areas for which evidence is abundant or lacking, to identify topics for which the available evidence is of low level or has a high risk of biased results, and to provide a high-level overview of the evidence landscape.
Please allow the map to load fully before interacting with other elements on the website.
Select one:
Download EGM
Level of evidence:
Level One
Level Two
Level Three
Level Four
Level Five
Unclassifiable

Disclaimer
Limitation of the EGMs: The EGMs presented in this section are based on abstract-level screening only. Full-text screening was not conducted, and therefore the inclusion of a study in an EGM should not be interpreted as confirmation that it fully meets pre-defined eligibility criteria. The EGMs are intended for exploratory and scoping purposes only and should not be used as a substitute for a full systematic review or as the sole basis for decision-making.
Please note that a publication record may be assigned to multiple levels of evidence (see the Methods Overview tab for details). Consequently, the same record may appear in more than one cell of the EGM. For this reason, the total number of records displayed across all cells may exceed the number of unique publication records included in the EGM.
About the AI-generated maps: Artificial intelligence (AI)-generated maps use the same framework as EGMs and can be used as visual tools that automatically display the published evidence on a topic across outcome domains, in this case tumour type (columns) and diagnostic tumour characteristics (rows). They can be used to explore areas for which evidence may be lacking, to identify topics for which the available evidence may be concentrated within specific evidence types, and to provide a high-level overview of the evidence landscape.
Please allow the map to load fully before interacting with other elements on the website.
Select one:
Download AGM
Level of evidence:
Level One
Level Two
Level Three
Level Four
Level Five
Unclassifiable

Disclaimer
Limitation of the AI-generated maps: The EGMs presented in this section were generated entirely using AI (large language models) and have not yet undergone human review or validation. Thus, the categorization, extraction, and mapping of studies may contain errors, omissions, or misclassifications. Therefore, the inclusion, placement, or interpretation of a study within an EGM should not be considered definitive and should be verified against the original source where necessary. These maps are intended for exploratory and scoping purposes only and should not be used as a substitute for an expert review or a full systematic review or as the sole basis for decision-making.
Please note that a publication record may be assigned to multiple levels of evidence (see the Methods Overview tab for details). Consequently, the same record may appear in more than one cell of the EGM. For this reason, the total number of records displayed across all cells may exceed the number of unique publication records included in the EGM.
About the citation maps: These maps are visual tools that display the body of evidence cited by the authors of the volumes of the fifth edition of the WHO Classification of Tumours (WCT). They provide an overview of the studies and evidence sources that informed the development of the classifications and can be used to explore the distribution and characteristics of the evidence referenced within the fifth edition of WCT.
Please allow the map to load fully before interacting with other elements on the website.
Select one:
Download CM
Level of evidence:
Level One
Level Two
Level Three
Level Four
Level Five
Unclassifiable

Disclaimer
Limitation of the citation maps: The citation maps presented in this section include only publications that were cited by authors of the volumes of the fifth edition of WCT and do not represent the entirety of the available evidence on a topic. Therefore, these maps should not be interpreted as EGMs and cannot be used to identify areas for which evidence is lacking, is abundant, or is of differing quality. The maps are intended solely to support examination of the evidence cited and used in the development of the fifth edition of WCT and should not be used as a substitute for a comprehensive assessment of the broader evidence landscape.
Please note that a publication record may be assigned to multiple levels of evidence (see the Methods Overview tab for details). Consequently, the same record may appear in more than one cell of the citation map. For this reason, the total number of records displayed across all cells may exceed the number of unique publication records included in the citation map.
Disclaimer
Limitation of the EGMs: Please note that a publication record may be assigned to multiple levels of evidence (see the Methods Overview tab for details). Consequently, the same record may appear more than once in the figures. For this reason, the total number of records displayed across all figures may exceed the number of unique publication records included in the EGMs.

Level of Evidence (LOE) in the selected articles


Loading...


Level of Evidence (LOE) over time in the selected articles


Loading...


WCT Characteristics in the selected articles


Loading...


WCT Characteristics over time in the selected articles


Loading...



Download Table

Loading...

Tumour type vs Level of Evidence


Loading...


Tumour type vs Characteristics


Loading...



Wordcloud




                    

EGM Examples


Project Partners

Funder
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the granting authority. Neither the European Union nor the granting authority can be held responsible for them.
Coordinator
Partners
Associated partners

Meet the Teams

IARC - International Agency for Research on Cancer

Coordinator | WP2, WP4, WP9, WP11

Dilani Lokuhetty

Head, WHO Classification of Tumours (WCT)

Iciar Indave

Principal investigator, WCT EVI MAP

Cécile Monnier

Project Assistant, WCT EVI MAP

Ramon Cierco Jimenez

Bioinformatics Specialist, WCT EVI MAP

Developer

Ian A. Cree

Senior Visiting Scientist

Christine Giesen

Visiting Scientist

Harshima Wijesinghe

Visiting Scientist

ISCIII - Instituto de Salud Carlos III

Beneficiary | WP6

Elena Plans Beriso

Principal Investigator

Oana Marilena Craciun

Doctoral Student

Ester García Ovejero

Doctoral Student

Marina Montes Mota

Biochemist

MSCI - Narodowy Instytut Onkologii

Beneficiary | WP5

Magdalena Chechlińska

Principal Investigator

Magdalena Kowalewska

Scientific Coordinator

Kateryna Maslova

Doctoral Student

Łukasz Taraszkiewicz

Doctoral Student

Paulina Kober

Maria Sromek

Mariusz Kulińczak

Agnieszka Janowska

Project Assistant

TUM - University Hospital German Heart Center

Beneficiary | WP7

Stefan Holdenrieder

Principal Investigator

Inga Trulson

Medical Doctor

Karolina Worf

Bioinformatician

Sophie Gruber

Doctoral Student

Laura Knoblauch

Medical Doctor

Silke Kraft

Project Assistant

SBSC - Singapore Breast Surgery Center

Associated Partner | WP8

Puay Hoon Tan

Principal Investigator

Nur Diyana Binte Md Nasir

Research Officer

Denise Hsin Yi Thng

Pathologist Assistant

Clarissa Wong Jing Wen

Medical Student

Zi Long Chow

Anatomical Pathology Registrar

Shi Ruoyu

Pathologist

Mervyn Ong

Clinical Research Coordinator

UNEW - University of Newcastle

Associated Partner | WP1

Fiona Campbell

Principal Investigator

UOXF - University of Oxford

Associated Partner | WP3, WP10

Richard Colling

Principal Investigator

Help & Tutorials

Short video tutorials and practical guidance to help you get the most from the WCT Evidence Explorer.

Learn how to use evidence gap maps (EGMs), navigate the dashboard, create customized EGMs, and explore the platform's key features through step-by-step tutorials.

Getting Started

Learn the basics of the platform, including navigation, functionalities, and available resources.

Exploring Maps

Discover how to explore map features, apply filters, interpret results, and access supporting evidence.

EGMs

Discover how to explore EGMs, AGMs, and CMs in the WCT Evidence Explorer.

Dashboard

Learn how to use dashboard indicators, visualizations, and evidence summaries to support decision-making.

EGM Builder

Step-by-step guidance on creating and managing customized evidence maps using the EGM Builder.

Methods Overview

The evidence gap maps (EGMs) and citation maps (CMs) included in the WCT Evidence Explorer were developed as part of the WCT EVI MAP project using systematic, transparent, and reproducible evidence synthesis methods. The EGMs provide a visual overview of recently published evidence for the WHO Classification of Tumours (WCT), across tumour types and tumour characteristics.

By applying the same domains used within the WCT framework, the maps aid understanding of the evidence base underpinning tumour classification, identify areas where low-level evidence is concentrated, and highlight important evidence gaps. The CMs additionally examine the evidence cited in support of the fifth edition of WCT, providing insights into the research that informed classification criteria previously.

Further information on the WCT EVI MAP methodology, protocols, publications, and project outputs is available on the WCT EVI MAP website: https://wct-evi-map.iarc.who.int/

The information below provides an overview of key definitions and classifications used throughout the maps to support their interpretation.
This table summarizes the tumour characteristics used across all maps and displayed in the rows of the EGMs. These characteristics correspond to the sections used to describe each tumour type within the WHO Classification of Tumours.
More detailed information is available in the WHO Classification of Tumours resources:
Name Definition Notes for clarification
Pathogenesis

The mechanisms – usually at the molecular and genetic level – by which a risk factor or other agent contributes to the development of a certain disease, or how the disease progresses to after its onset. Often combined studies (e.g. molecular epidemiology) using both epidemiological and laboratory methods to examine causation or pathogenesis.

We include here direct studies of causation in patients, samples, cell or animal models, often using laboratory methods and also combined studies (e.g. molecular epidemiology) using both epidemiological and laboratory methods to examine causation or pathogenesis.

The pathogenesis of a disease describes the mechanisms by which it develops, progresses, and either persists or is resolved.
Diagnostic Imaging

Medical or diagnostic imaging technologies used to study the human body for the purpose of diagnosing, monitoring, or treating medical conditions. Technics include X-rays, ultrasound, computed tomography (CT) and magnetic resonance (MR), Molecular Imaging such as Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET), as well as mixed technics as SPECT/CT, PET/CT and PET/MR. These are powerful tools for the diagnosis of several health conditions, in particular cancer, allowing the visualization, characterisation and quantification of anatomical lesions or biologic events that occur at early stages of disease.

Endoscopy is not included.
Histopathology Microscopic examination of tissue, usually with diagnostic intent, including several techniques, such as direct observation, various histologic methods and microscopic technics, including immunohistochemistry.
Cytopathology Cytology (also known as cytopathology) is the microscopic examination of cells aspirated from tissue or obtained from bodily tissues or fluids various cytologic methods and microscopic technics, including immunocytochemistry to determine a diagnosis.
Diagnostic molecular pathology Application of molecular tests or molecular techniques to correctly identify molecular alterations of diagnostic significance in tumours. Laboratory methods that are used to help identify a disease or the risk of developing a disease, such as cancer, by studying molecules, such as DNA, RNA, and proteins, in a tissue or fluid sample. Molecular diagnostics may also be used to help plan treatment for a disease, look for recurrence of disease, or find out how well treatment is working. There are many types of molecular diagnostic tests, such as biomarker tests, genetic tests, tumour sequencing tests, and liquid biopsies.
Prognosis Prognosis involves assessing the likely course and outcome of a disease once it is diagnosed regardless of the treatment applied. This domain focuses on determining the severity of the disease and predicting its future progression, which helps in planning treatment and anticipating health outcomes. Risk factors affecting progression or survival are included here. Prognostic factors may be defined by association with a clinical outcome in the absence of therapy or with the application of a standard therapy.
Prediction Studies evaluating the relationship between certain tumour biomarker characteristic and the expected patient’s response to a certain treatment or intervention, compared to that in the absence of this biomarker characteristic. Various factors and tests utilizing various laboratory technics can be included into this category. Predictive factors are associated with the response to a particular therapy. They imply a differential benefit of therapy that is dependent on the value of tumour (including tumour environment) or patient related factors (Histology, TNM, Grading, Hormone Receptor Status, Molecular Characteristics, Cellular or body fluid-based biomarkers).

This table summarizes the criteria used to classify the identified publications by study design, based on the decision tree developed within the WCT EVI MAP project. The classification framework was designed specifically for tumour pathology research to support consistent categorization of studies across evidence maps.
More detailed information is available in:
Craciun OM, García-Ovejero E, Campbell F, Montes-Mota M, Holdenrieder S, Trulson I, et al.; WCT EVI MAP Project Team (2026). Development of a decision tree diagram for classifying study designs in tumour pathology research: a multidisciplinary approach. J Pathol Clin Res. 12(1):e70056. https://doi.org/10.1002/2056-4538.70056 PMID:41317315 .
Name Definition Notes for clarification
Consensus, statements or clinical guidelines

Consensus Study: An original study which seeks a consensus among experts using a formal methodology such as a Delphi study, an online or in person survey or voting process (consensus conference) and published as a position statement/recommendation. This is distinct from simple published surveys, letters to editors or opinion articles.

Clinical Practice Guidelines are defined as systematically developed statements or processes to assist clinician and patient decisions about appropriate health care for specific clinical circumstances. We will include if the abstract states ‘guideline or statement’ developed by a panel of experts or professional societies or official institutions or its abstract refers to the use of some systematic methods for the development of clinical practice guidelines or recommendations (i.e. GRADE, IOM Standards, G-I-N Standards or Guidelines 2.0).

Systematic Review

A review of the scientific evidence which applies strategies that limit bias in the assembly, critical appraisal, and synthesis of all relevant studies on the specific topic. With meta-analysis: systematic review followed by a statistical analysis of results from separate studies, examining sources of differences in results among studies, and leading to a quantitative summary of the results if the results are judged sufficiently similar or consistent to support such synthesis.

This code includes also: Umbrella Review. Umbrella Reviews or Overviews of Reviews are reviews of systematic reviews. Overviews are often broader in scope than any individual systematic review, meaning that they can examine a broad range of evidence.

Animal Study (mechanistic)

A study that uses animals or animal samples (including cell lines) as research subject including xenograft models (models of cancer where the human tissue or cells are implanted into an animal). Studies carried out in the areas of basic research (mechanistic studies) and medicine referring to human oncology. Research concerning veterinary medicine purposes are to be excluded.

Other Mechanistic Basic Science Studies

Studies without clinical data associated. In vitro/in silico studies that use human derived samples for fundamental/basic science/biological experimental work (such as living cells lines or tissues, molecules, or studies using organoids, three-dimensional miniature versions of organs or tissues generated from cells with stem potential). This does not include studies of clinical tests carried out in the lab on patient tissues taken for clinical purposes (these are considered in vivo clinical/epidemiological or diagnostic studies instead).

Are included here:

  1. In silico studies: computer simulation or evaluations of synthetic data with known properties.
  2. Molecular database derived studies: Databases from cohort or case-control consortia are considered human data (i.e., Practical, TGCA). The rest of studies using data derived from online molecular, genetic, or another biological database repository are included here.
Ecological Study

A study in which the units of analysis are populations or groups of people rather than individuals (aggregated data). Geographical comparisons with aggregated outcomes such as temporal trends including joinpoint analysis, time series, interrupted time series and correlations between aggregated variables.

Case Report

Detailed description of observations at the individual level, documented from a single patient or clinical case. This code also includes small case series with less than five subjects (n<5).

Case Series/Longitudinal Case Series

Case series: A collection of subjects (usually patients) with common characteristics used to describe some clinical, pathophysiological, or operational aspect of a disease, treatment, exposure, or diagnostic procedure. Without non-tumoral comparison group.

Longitudinal case series: A single-group research design in which measurements are made at several different times, thereby allowing trends to be detected.

Population-based Descriptive Study

Population-based Descriptive Study: Studies carried out from Population-based Cancer Registries (or other population-based registries, i.e. official country mortality data) that seek to describe a population group, but without a comparison group (there may be comparisons based on sociodemographic variables such as sex, age, or ethnic groups). A hospital registry is not a population-based registry.

Diagnostic Test Agreement/Reproducibility Study

A study where the repeatability (reproducibility) of a specific diagnostic test or procedure is evaluated by multiple observers (pathologists or others) or machines (image analysis, AI), or their combination. This may take the form of a test being repeated multiple times on the same cases at different time points or, more often, where different observers (e.g., a group of pathologists) evaluate and interpret/report the results of the test independently. The results of repeated testing are compared between the observers. Sometimes diagnostic agreement/reproducibility design may accompany diagnostic accuracy studies.

Laboratory Test Validation Study

These studies validate the performance of a laboratory test or assay in a controlled laboratory environment (i.e., pathology laboratory), usually in cherry-picked cases/samples. The focus is primarily on the technical aspects of the laboratory method to ensure that it produces consistent and valid results when compared to the reference method. These studies are foundational for ensuring that a test is suitable for further clinical evaluation.

Diagnostic Test Accuracy Study

These studies evaluate the effectiveness and reliability of diagnostic tests in the clinical settings and focus on their ability to accurately detect the presence or absence of a particular disease or condition. The focus here is on the clinical utility of the test, i.e., assessing how well it helps to make accurate diagnostic decisions for a specific clinical question/situation. Therefore, the identification of selected patients and controls is mandatory as well as a comprehensive statistical analysis.

Key metrics used in these studies must include at least one of these options:

  1. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve.
  2. Sensitivity, specificity, PPV, NPV: at least two of them and with 95% confidence interval (CI 95%).
  3. Sensitivity, specificity, PPV, NPV: all of them without CI 95%.

These studies are designed to quantify the performance of a test in a clinical setting and inform clinicians about the reliability of the test for making diagnostic decisions.

Randomized Controlled Trial

A clinical-epidemiological experiment in which subjects are randomly allocated into groups, usually called intervention/test and control groups, to receive or not to receive a preventive or a therapeutic procedure or intervention.

Other Clinical Trial

A clinical-epidemiological experiment in which subjects are not randomly allocated into groups, to receive or not to receive a preventive or a therapeutic procedure or intervention.

Includes several types of study:

  1. Quasi-experimental: situation in which the investigator lacks full control over the allocation and/or timing of intervention but nonetheless conducts the study as if it were an experiment, allocating subjects to groups.
  2. Single-arm trials, with no control group.
  3. Historical control: The control group are subjects who were studied before the main group receive the intervention.
  4. Experimental before-after studies: An approach in which the outcome is measured before and after an intervention that has been delivered to all participants.
Observational Longitudinal Study RCT derived

The information and/or samples collected in an RCT are used to test a different hypothesis (i.e. the prognostic value of a biomarker). Patients were not randomized according to the new objective, so it is an observational study taking advantage of the systematic collection of data and the quality control measures usually included in RCTs.

Cohort study

Study design in which the investigator observes participants (free of the event that is going to be evaluated) who are exposed and unexposed and follows them up to see if they develop the disease or event of interest. In a cohort study, the investigator observes and does not assign the participants’ exposure status as in the experimental design. They could be prospective or retrospective (conducted by reconstructing data about participants at a time or times in the past).

Includes Nested Case-Control and Case-Cohort studies
Other Longitudinal Studies

Observational before-after Study: An approach in which the outcome is measured before and after an exposure has occurred to all participants. In contrast to the experimental ones, the exposure is not defined by the researcher.

Other follow up studies: other longitudinal studies that do not meet the stated criteria for cohorts, they may compute percentage of survival patients or other index typical of cohort studies, but without controlling losses of follow-up and/or using survival analytical methods.

Self-matched Case-Control Study

In this design, each participant (case) serves as its own matched control. I.e., when the tumour tissue from a cancer case is compared with the corresponding “healthy” tissue from the same patient to assess the association between some characteristic/feature/exposure with the outcome (disease or cancer subtype).

Cross-Sectional Study

Study in which the outcome and other variables are determined in each participant of the study at one particular time. It can refer to a period, however observed photographically (without evolution).

There is no formal selection of controls, this means that firstly the participants are recruited and only after that, they are classified depending on their diagnosis into the comparison groups (sometimes referred as cases and controls). Comparisons of histological, immunohistochemical, genetic, etc. profiles between groups of tumours are included here (exception: in this case it is considered cross-sectional even with a formal selection of controls).

Classic Case-Control Study

Study design in which the investigator selects participants with the outcome (cancer type or subtype) (cases) and a comparison group without that particular outcome (controls) to study the association between previous exposures or previous characteristics with the outcome. Cases and controls are very often matched by age, sex, or other variables.


This table presents the adapted Hierarchy of Research Evidence for Tumour Pathology, developed through an international Delphi consensus study conducted as part of the WCT EVI MAP project. The framework provides a structured approach for assessing the studies included in the maps based on the risk of bias inherently associated with different study designs. It enables us to assign a level of evidence to each mapped publication and group them according to this aspect of methodological quality, facilitating the interpretation of the overall evidence base.
More detailed information is available in:
Colling R, Indave I, Del Águila J, Jimenez RC, Campbell F, Chechlińska M, et al. (2024). A new hierarchy of research evidence for tumor pathology: a Delphi study to define levels of evidence in tumor pathology. Mod Pathol. 37(1):100357. https://doi.org/10.1016/j.modpat.2023.100357 PMID:37866639 .
WCT characteristics Diagnostic imaging Pathogenesis Histopathology Molecular Diagnostic Features Prognosis Prediction
Research focus Clinical characteristics of the tumour Biological development and progression Pathological characterisation (macro- and micro-) Molecular characterisation Prognostics Factors predicting response to treatment
Example questions What is the anatomical localisation of the primary tumor?
What are the signs and symptoms of the tumor?
What does the tumor look like and how it interacts with surrounding tissues (X-rays, CT, MRI, PET, US)?
What are the mechanisms through which the tumour arises and progresses?
What biological processes, at the cellular, molecular, or genetic levels, lead to the development and progression of the tumour?
What is the appearance of the tumour following surgical removal?
What are the microscopic features, i.e. structural and cellular patterns, that indicate disease?
What are the appearance and characteristics of cells aspirated from a tissue or body fluids?
How well does this test confirm the diagnosis compared with a gold standard?
AND / OR
Is there consistency when applying the diagnostic test several times to the same subject/sample?
What biomolecules (eg. DNA, RNA, proteins, epigenetic changes) characterise cells, tissues and body fluids for the diagnosis of tumours?
How well does this test confirm the diagnosis compared with a gold standard?
AND / OR
Is there consistency when applying the diagnostic test several times to the same subject/sample?
What is the likely course and outcome of the tumour once it is diagnosed, regardless of the treatment applied?
What features influence progression or overall survival?
Does this feature/biomarker identify patients who are likely to respond to treatment?
Level 1 Systematic review Systematic review Systematic review Systematic review Systematic review Systematic review
Level 2 Population-based descriptive study
Observational longitudinal RCT-derived study
Cohort study
Observational longitudinal RCT-derived study
Cohort study
Self-matched case-control study
Population-based descriptive study
Randomized controlled trial (RCT)
Observational longitudinal RCT-derived study
Cross-sectional study
Population-based descriptive study
Randomized controlled trial (RCT)
Observational longitudinal RCT-derived study
Diagnostic test accuracy study
Diagnostic test agreement / reproducibility study
Population-based descriptive study
Randomized controlled trial (RCT)
Observational longitudinal RCT-derived study
Cohort study
Randomized controlled trial (RCT)
Observational longitudinal RCT-derived study
Cohort study
Level 3 Classic case-control study
Cross-sectional study
Other cohorts & other longitudinal studies
Diagnostic test accuracy study
Diagnostic test agreement / reproducibility study
Classic case-control study
Cross-sectional study
Other cohorts & other longitudinal studies
Cohort study
Classic case-control study
Self-matched case-control study
Diagnostic test accuracy study
Diagnostic test agreement / reproducibility study
Cohort study
Classic case-control study
Cross-sectional study
Self-matched case-control study
Non-randomized controlled trial
Other cohorts & other longitudinal studies
Case series / longitudinal case series
Non-randomized controlled trial
Other cohorts & other longitudinal studies
Level 4 Self-matched case-control study
Case series / longitudinal case series
Laboratory test validation study
Ecological study
Case series / longitudinal case series
Other mechanistic basic science studies
Animal study (mechanistic)
Other cohorts & other longitudinal studies
Case series / longitudinal case series
Laboratory test validation study
Other cohorts & other longitudinal studies
Case series / longitudinal case series
Laboratory test validation study
Cross-sectional study
Classic case-control study
Ecological study
Cross-sectional study
Classic case-control study
Case series / longitudinal case series
Ecological study
Level 5 Case report Case report Case report Case report Case report Case report
Unclassifiable Big picture reviews
Consensus, statements, or clinical guidelines,
& other study designs not included in cells above
Big picture reviews
Consensus, statements, or clinical guidelines,
& other study designs not included in cells above
Big picture reviews
Consensus, statements, or clinical guidelines,
& other study designs not included in cells above
Big picture reviews
Consensus, statements, or clinical guidelines,
& other study designs not included in cells above
Big picture reviews
Consensus, statements, or clinical guidelines,
& other study designs not included in cells above
Big picture reviews
Consensus, statements, or clinical guidelines,
& other study designs not included in cells above